Organization
Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea
58 abstracts
Abstract
Phase IB/II trial of durvalumab plus doxorubicin combination in patients with advanced soft-tissue sarcoma.Org: Department of Biomedical Convergence Science and Technology, Kyungpook National University, Daegu, South Korea, Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, South Korea, Department of Pathology, Yonsei University College of Medicine, Seoul, South Korea, Department of Radiology, Yonsei University College of Medicine, Seoul, South Korea, Division of Hematology-Oncology, Department of Medicine, Seoul Medical Center, Seo-Gu, South Korea,
Abstract
A phase 1 trial in progress for in situ immunomodulation with CDX-301, radiation therapy, poly-ICLC, and CDX-1140 in patients with unresectable and metastatic solid tumors.Org: Norris Comprehensive Cancer Center, Keck School of Medicine of the University of Southern California, University of Southern California Marshall School of Business, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Division of Oncology, Rambam health care, Haifa, Israel,
Abstract
Predictive markers of complete pathological response to neoadjuvant chemo-immunotherapy in triple negative breast cancer.Org: Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Institute of Oncology Ljubljana,
Abstract
Efficacy and toxicity of BRAF targeted therapy in elderly patients with melanoma.Org: Mayo Clinic, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Mayo Clinic Florida, Mayo Clinic Arizona,
Abstract
A phase 3, randomized study of adjuvant rilvegostomig plus chemotherapy in resected biliary tract cancer: ARTEMIDE-Biliary01.Org: Mayo Clinic Comprehensive Cancer Center, IRCCS San Raffaele Hospital, UCL Cancer Institute, Cedars-Sinai Medical Center, Memorial Sloan Kettering Cancer Center,
Abstract
Results of a phase 2 study of evorpacept (E, ALX148), cetuximab (C), and pembrolizumab (P) in patients with refractory microsatellite stable metastatic colorectal cancer (MSS CRC).Org: University of Colorado Cancer Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Department of Medicine, Icahn School of Medicine at Mount Sinai, University of Colorado Anschutz Medical Campus, Inova Schar Cancer Institute,
Abstract
Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC.Org: Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, National Cancer Centre Singapore, Department of Clinical Oncology, Queen Elizabeth Hospital, The Chinese University of Hong Kong, Prince of Wales Hospital,
Abstract
Efficacy and toxicity of KIT targeted therapy in elderly patients with melanoma.Org: Mayo Clinic, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Mayo Clinic Florida,
Abstract
A phase II study of nivolumab in patients with recurrent or metastatic carcinosarcomas.Org: Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Seoul National University Hospital, Division of Hematology-Oncology, Department of Medicine, Seoul Medical Center, Seo-Gu, South Korea, Department of Medicine, Icahn School of Medicine at Mount Sinai, Samsung Medical Center,
Abstract
Association between somatic mutation pathways and treatment response in patients with biliary tract cancers (BTCs).Org: Beth Israel Deaconess Medical Center, Mount Sinai Beth Israel, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Department of Medicine, Icahn School of Medicine at Mount Sinai,
Abstract
Time to target TIM-3 in colorectal cancer: TIM-3 expression to predict survival outcomes in patients in CALGB (Alliance)/SWOG 80405.Org: Norris Comprehensive Cancer Center, University of Southern California Marshall School of Business, Los Angeles Medical Center, Keck School of Medicine of the University of Southern California, Department of Population and Public Health Sciences,
Abstract
Retrieval-augmented large language models for clinical trial screening.Org: Memorial Sloan Kettering Cancer Center, National University of Singapore, National Cancer Centre Singapore, Singapore General Hospital and SingHealth Duke NUS Blood Cancer Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea,
Abstract
Survival and mutational differences based on ESR1 and ESR2 expression in non-small cell lung cancer (NSCLC).Org: Norris Comprehensive Cancer Center, University of Southern California Marshall School of Business, Caris Life Sciences, Irving, TX, University of California, Irvine Medical Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea,
Abstract
Improving diversity in phase I oncology clinical trials: A single institution experience at the University of Colorado Cancer Center.Org: School of Medicine, Zhejiang University, Hangzhou, China, University of Colorado Anschutz Medical Campus, Division of Gynecologic Oncology, University of Pennsylvania, Department of Obstetrics & Gynecology, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea,
Abstract
Clinical characteristics and treatment outcomes in Hispanic/Latino patients with advanced renal cell carcinoma at a single institution.Org: University of Miami Miller School of Medicine, Miami, FL, Jackson Memorial Hospital, Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Sylvester Comprehensive Cancer Center, Miami, FL,
Abstract
Neoadjuvant immuno-chemotherapy in resectable non-small cell lung cancer: A retrospective cohort study.Org: Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, London Regional Cancer Program, Schulich School of Medicine and Dentistry, Western University, London Health Sciences Centre,
Abstract
Long term outcomes in patients with recurrent/metastatic (R/M) salivary gland cancer (SGC) treated with immune checkpoint inhibitors (ICI).Org: Fred Hutchinson Cancer Center, Seattle, WA, University of Washington and Fred Hutchinson Cancer Research Centre, Division of Hematopathology, Mayo Clinic, Rochester, MN, Virginia Commonwealth University School of Medicine,
Abstract
Screening for ocular toxicities of immunotherapy in a real-world population.Org: School of Medicine, Zhejiang University, Hangzhou, China, Department of Ophthalmology, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea,
Abstract
Alliance A091902: A multicenter randomized phase II trial of paclitaxel (P) with or without nivolumab (N) in patients (pts) with advanced angiosarcoma (AS).Org: Duke Cancer Institute, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Durham, NC, Mayo Clinic, Rochester, MN,
Abstract
Phase Ib study of neoadjuvant concurrent chemoradiation plus durvalumab followed by surgery and adjuvant durvalumab for resectable stage III NSCLC.Org: Lung Cancer Center, Yonsei Cancer Center, Yonsei University Health System, Yonsei University College of Medicine, Heavy Ion Research Institute, Department of Thoracic and Cardiovascular Surgery,
Abstract
Dual PD1 and CTLA4 immune checkpoint blockade and hypofractionated radiation in patients with salivary gland cancers.Org: University of Washington and Fred Hutchinson Cancer Research Centre, Fred Hutchinson Cancer Research Center, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Division of Hematopathology, Mayo Clinic, Rochester, MN, Virginia Commonwealth University School of Medicine,
Abstract
Decreasing the burden of febrile neutropenia through dynamic remote patient monitoring: The DEFeNDER program.Org: Mayo Clinic, Department of Quantitative Science Research, Mayo Hosp, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ,
Abstract
Efficacy and safety study of neoadjuvant efineptakin alfa (NT-I7) and pembrolizumab in recurrent glioblastoma.Org: Mayo Clinic, Alliance Statistics and Data Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Department of Neurology, Brigham and Woman’s Hospital, Harvard Medical School, Boston, MA, Mayo Clinic Cancer Center,
Abstract
Genomic landscapes to characterize mismatch-repair deficiency (dMMR)/microsatellite instability-high (MSI-H) gastrointestinal (GI) cancers stratified by tumor mutation burden (TMB).Org: Norris Comprehensive Cancer Center, Keck School of Medicine of the University of Southern California, University of Southern California Marshall School of Business, Caris Life Sciences, Irving, TX, Department of Preventive Medicine,
Abstract
A phase I study of nelmastobart (hSTC810), an anti-BTN1A1 antibody, in patients with advanced solid tumors.Org: Korea University Anam Hospital, Yonsei Cancer Center, Yonsei University Health System, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Yonsei University College of Medicine,
Abstract
Safety and efficacy of D-1553 in KRAS G12C-mutated colorectal cancer: Results from a phase I/II study.Org: Sun Yat-sen University Cancer Center Gansu Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Collaborative Innovation Center for Cancer Medicine, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea,
Abstract
A phase 1/2, first-in-human trial of ZB131, a novel antibody targeting cancer-specific plectin (CSP) in advanced solid tumors.Org: Next Oncology Virginia and Virginia Cancer Specialists, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC,
Abstract
Single nucleotide polymorphisms (SNPs) in MHC class I and II genes to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3, MAVERICC, and TRIBE trials.Org: Bayer AG, Charité - Universitätsmedizin Berlin, Berlin, Germany, University of Munich, University of Pisa & Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Germany,
Abstract
The number of lymph nodes examined as a poor prognosis factor in stage II and stage III colon cancer patients undergoing curative surgery.Org: Yonsei University College of Medicine, Netherlands Comprehensive Cancer Organisation (IKNL), Yonsei Cancer Center, Yonsei University Health System, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany,
Abstract
A phase 1 study of AGEN2373, a novel CD137 agonist antibody designed to avoid hepatoxicity, in patients with advanced solid tumors.Org: Mary Crowley Cancer Research Center, Dallas, Next Oncology Virginia and Virginia Cancer Specialists, San Antonio Breast Cancer Symposium, Northwell Health Cancer Institute,
Abstract
The metabolic activity assessed by 18F-FDG PET and its correlation with tumor immune status and prognosis in advanced biliary tract cancer patients treated with 1L GemCis plus durvalumab +/-tremelimumab.Org: Medical Oncology Group, Seoul National University Hospital, Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany,
Abstract
Racial and socioeconomic disparities in time to chemotherapy and survival in patients with pancreatic cancer.Org: Allegheny General Hospital, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Allegheny Health Network Cancer Institute, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea,
Abstract
Pembrolizumab, radiotherapy, and chemotherapy in neoadjuvant treatment of malignant esophago-gastric diseases (PROCEED): Assessment of pathologic response and toxicity in a prospective, phase II single-arm trial.Org: Duke Cancer Institute, Duke University Medical Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC,
Abstract
Genomic landscapes of early-onset versus average-onset colorectal cancer populations.Org: Mayo Clinic, Department of Quantitative Science Research, Vanderbilt-Ingram Cancer Center, University of Colorado Cancer Center, Tempus Labs, Inc.,
Abstract
The Maverick trial: A phase 2 study of abivertinib in patients (pts) with metastatic castration resistant prostate cancer (mCRPC).Org: Sorrento Therapeutics Inc., Sorrento Therapeutics, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Duke Cancer Institute, Carbone Cancer Center, University of Wisconsin, Madison, WI,
Abstract
Neoadjuvant T-VEC + nivolumab combination therapy for resectable early metastatic (stage IIIB/C/D-IV M1a) melanoma with injectable disease: NIVEC trial.Org: Division of Surgical Oncology, Department of Surgery, The Ohio State University, Netherlands Cancer Institute, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, The Netherlands Cancer Institute,
Abstract
Infrastructure for rare cancer in the Netherlands: Towards a comprehensive platform for early detection and diagnosis of rare cancers (FORCE).Org: The Netherlands Cancer Institute, Amsterdam/UMC Utrecht ENETS Centre of Excellence, Department of Endocrine Oncology, University Medical Center Groningen, Máxima Medical Center,
Abstract
PolyPEPI1018 vaccine in combination with TAS-102 in participants with late-stage microsatellite-stable metastatic colorectal cancer (MSS mCRC): A phase Ib study to evaluate safety, tolerability, immunogenicity and efficacy (OBERTO-201).Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Mayo Clinic, Rochester, MN, Department of Laboratory Medicine and Pathology, University of Washington, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea,
Abstract
Positive margin and advanced depth of invasion as the indicators for assessing the necessity of adjuvant chemoradiotherapy in early-stage oral cavity squamous cell carcinoma.Org: Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Chung Shan Medical University Hospital, Department of Dentistry, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China,
Abstract
Prognostic value of systemic inflammatory response in early-stage triple-negative breast cancer.Org: Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Institute of Oncology Ljubljana,
Abstract
Osimertinib rechallenge in advanced EGFR non-small cell lung cancer patients.Org: University of Washington and Fred Hutchinson Cancer Research Centre, Fred Hutchinson Cancer Research Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, University of Washington School of Medicine,
Abstract
Osimertinib then chemotherapy in EGFR-mutated lung cancer with osimertinib third-line rechallenge (OCELOT).Org: Schulich School of Medicine and Dentistry, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, London Regional Cancer Program, University Health Network,
Abstract
Integrated efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC in the ALTA-1L and J-ALTA studies.Org: University of Colorado Cancer Center, Sendai Kousei Hospital, Fujita Health University School of Medicine, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Yonsei Cancer Center, Yonsei University Health System,
Abstract
Amivantamab and lazertinib in treatment-naïve EGFR-mutated advanced non–small-cell lung cancer (NSCLC): Long-term follow-up and ctDNA results from CHRYSALIS.Org: Samsung Medical Center, Sungkyunkwan University School of Medicine, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Yonsei Cancer Center, Yonsei University Health System, Yonsei University College of Medicine,
Abstract
De-correlating immune checkpoint inhibitor toxicity and response in melanoma via the microbiome.Org: Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, The Ohio State University - James Cancer Hospital, Ohio State University College of Medicine, The Ohio State University Medical Center,
Abstract
Impact of immunotherapy on intracranial progression-free survival in patients with advanced lung cancer and melanoma with brain metastasis: A single-center retrospective study and comparison of the pre- and post-immunotherapy era.Org: Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, East Tennessee State University Quillen College of Medicine, Department of Epidemiology and Data Science, East Tennessee State University College of Public Health, Ballad Health Cancer Care,
Abstract
Association between symptoms and health-related quality of life in patients with cancer with prior or ongoing immune checkpoint inhibitor therapy exposure.Org: Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Seattle, WA, University of Washington and Fred Hutchinson Cancer Research Centre, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Treatment Technologies & Insights,
Abstract
A comparison study of solid tumor, malignant hematology, and general medicine inpatient services.Org: The Ohio State University - James Cancer Hospital, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, The James Cancer Hospital and Solove Research Institute, The Ohio State University Medical Center,
Abstract
Characterizing non-small cell lung cancer driven by mutations in ARAF and CRAF family members.Org: Ohio State University Comprehensive Canvcer Hospital, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, James Thoracic Center, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH,
Abstract
Evaluating response to interventions for vasomotor symptoms in patients with breast cancer: A patient-centered approach.Org: Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Department of Medicine, Icahn School of Medicine at Mount Sinai, Cancer Therapeutics Program, The Ottawa Hospital Research Institute, Ottawa Hospital Research Institute,
Abstract
Longitudinal variability in symptom burden for patients with prostate cancer (PC).Org: Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Hematology/Oncology, Department of Medicine, University Of Toledo, University of Pittsburgh, Pittsburgh, PA, Pittsburgh, PA, PainReform,
Abstract
The impact of DNA damage repair gene mutations on therapeutic response among Chinese patients diagnosed with advanced biliary tract cancer.Org: Gastric Cancer Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Laboratory of Gastric Cancer, State Key Laboratory of Biotherapy,
Abstract
RAMP 202: A phase 2 study of avutometinib (VS-6766) ± defactinib, in patients with advanced KRAS G12V mutant non–small cell lung cancer (NSCLC).Org: Lombardi Comprehensive Cancer Center, Georgetown University Medical School, Washington, DC, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, Lecanto, FL,
Abstract
Molecular and clinical characteristics of patients with KRAS mutated pancreatic ductal adenocarcinoma.Org: Mayo Clinic-Rochester, Mayo Clinic Rochester, Rochester, MN, Mayo Clinic, UH Seidman Cancer Center, Case Western Reserve University School of Medicine,
Abstract
Use of direct oral anticoagulants (DOACs) in oncology: A phase IV study on impact of edoxaban treatment in Italian patients with cancer with venous thromboembolism during antineoplastic therapy (EDOI trial, GOIRC 05-2018).Org: IRCCS AUSL Reggio Emilia, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, University of Turin at Ordine Mauriziano Hospital, Medical Oncology Unit, Ramazzini Hospital, Carpi, Italy, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland,
Abstract
Investigation of the prognostic significance of CD5, CD117, EZH2, POU2F3, MTAP and BAP1 in thymic carcinoma.Org: Mayo Clinic, Department of Laboratory Medicine and Pathology, University of Washington, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Division of Thoracic Surgery, Brigham and Women's Hospital, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea,
Abstract
Efficacy of immunotherapy in MSI metastatic colorectal cancer patients: A Real-World Italian multicentric retrospective study (Colon-MSI Study).Org: Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa & Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy, Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana and Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy, Charité Universitätsmedizin Berlin, Berlin, Germany, Oncology Unit 1, Veneto Institute of Oncology IOV – IRCCS, Padua, Italy, Department of Medical Oncology, University Campus Biomedico, Roma, Italy, Division of Clinical Pharmacology and Oncology, Department of Health Sciences, School of Psychology, University of Florence, Florence, Italy, University of Pisa, Pisa, Italy, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy and Oncology Unit 1 Veneto Institute of Oncology - IRCCS Padua, Padua, Italy, U.O.C. Oncologia Medica, Presidio Ospedaliero Livorno, Livorno, Italy, Hämatologisch Onkologische Praxis Eppendorf (HOPE) and Universitäres Cancer Center Hamburg, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy, Department of Oncology, Istituto Scientifico San Raffaele IRCSS, Milan, Italy, CdC Poliambulanza, Brescia, Italy, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy and Oncology Unit 1 Veneto Institute of Oncology - IRCCS, Padua, Italy, IRCSS-CRO Aviano, Department of Clinical Oncology, Aviano, Italy, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Martin Luther University, Halle, Germany, Azienda Ospedaliero-Universitaria Pisana, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy,
Abstract
Understanding the late immune checkpoint inhibitor (ICI) symptom experience using an electronic patient reported outcomes (ePRO) app-based platform: The Immunowave study.Org: University of Washington and Fred Hutchinson Cancer Research Centre, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Wave Health,